Myung In Pharmaceutical LTD. (KRX:317450)
South Korea
· Delayed Price · Currency is KRW 56,200
-500 (-0.88%)
At close: Apr 28, 2026
KRX:317450 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 287,254 | 269,435 | 242,338 | 225,828 | 209,250 | Upgrade
|
| Other Revenue | -0 | - | - | -0 | -0 | Upgrade
|
| Revenue | 287,254 | 269,435 | 242,338 | 225,828 | 209,250 | Upgrade
|
| Revenue Growth (YoY) | 6.61% | 11.18% | 7.31% | 7.92% | 11.40% | Upgrade
|
| Cost of Revenue | 113,269 | 100,556 | 88,413 | 82,280 | 70,954 | Upgrade
|
| Gross Profit | 173,985 | 168,879 | 153,925 | 143,549 | 138,297 | Upgrade
|
| Selling, General & Admin | 71,553 | 67,800 | 62,249 | 57,227 | 57,643 | Upgrade
|
| Research & Development | 5,152 | 3,684 | 4,037 | 4,749 | 2,448 | Upgrade
|
| Amortization of Goodwill & Intangibles | 1.32 | 1.15 | 0.98 | 1.25 | 1.53 | Upgrade
|
| Other Operating Expenses | 1,683 | 1,588 | 1,485 | 3,564 | 1,326 | Upgrade
|
| Operating Expenses | 81,487 | 76,124 | 70,306 | 67,646 | 64,091 | Upgrade
|
| Operating Income | 92,498 | 92,754 | 83,618 | 75,903 | 74,206 | Upgrade
|
| Interest Expense | -235.34 | -322.65 | -333.54 | -106.64 | -133.33 | Upgrade
|
| Interest & Investment Income | 9,215 | 8,621 | 6,218 | 2,916 | 835.94 | Upgrade
|
| Currency Exchange Gain (Loss) | 435.19 | 5,490 | 1,204 | 2,687 | 4,063 | Upgrade
|
| Other Non Operating Income (Expenses) | 185.13 | -9,548 | 527.79 | 406.58 | 797.02 | Upgrade
|
| EBT Excluding Unusual Items | 102,099 | 96,994 | 91,235 | 81,806 | 79,768 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -8,310 | 826.42 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 20.99 | -609.54 | -0.32 | 10.7 | 6.39 | Upgrade
|
| Pretax Income | 102,120 | 88,075 | 92,061 | 81,817 | 79,775 | Upgrade
|
| Income Tax Expense | 20,684 | 19,404 | 17,550 | 24,383 | 20,024 | Upgrade
|
| Net Income | 81,435 | 68,671 | 74,512 | 57,434 | 59,750 | Upgrade
|
| Net Income to Common | 81,435 | 68,671 | 74,512 | 57,434 | 59,750 | Upgrade
|
| Net Income Growth | 18.59% | -7.84% | 29.73% | -3.88% | 31.38% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | 8.23% | 0.01% | - | - | - | Upgrade
|
| EPS (Basic) | 6718.00 | 6131.00 | 6652.82 | 5128.04 | 5334.82 | Upgrade
|
| EPS (Diluted) | 6718.00 | 6131.00 | 6652.82 | 5128.04 | 5334.82 | Upgrade
|
| EPS Growth | 9.57% | -7.84% | 29.73% | -3.88% | 31.38% | Upgrade
|
| Free Cash Flow | 51,522 | 72,783 | 71,428 | 57,643 | 63,407 | Upgrade
|
| Free Cash Flow Per Share | 4250.33 | 6498.19 | 6377.48 | 5146.68 | 5661.37 | Upgrade
|
| Dividend Per Share | - | - | 2000.000 | 1000.000 | 1250.000 | Upgrade
|
| Dividend Growth | - | - | 100.00% | -20.00% | -28.57% | Upgrade
|
| Gross Margin | 60.57% | 62.68% | 63.52% | 63.57% | 66.09% | Upgrade
|
| Operating Margin | 32.20% | 34.43% | 34.51% | 33.61% | 35.46% | Upgrade
|
| Profit Margin | 28.35% | 25.49% | 30.75% | 25.43% | 28.55% | Upgrade
|
| Free Cash Flow Margin | 17.94% | 27.01% | 29.47% | 25.52% | 30.30% | Upgrade
|
| EBITDA | 103,439 | 105,217 | 95,058 | 87,238 | 85,824 | Upgrade
|
| EBITDA Margin | 36.01% | 39.05% | 39.23% | 38.63% | 41.02% | Upgrade
|
| D&A For EBITDA | 10,940 | 12,463 | 11,440 | 11,336 | 11,619 | Upgrade
|
| EBIT | 92,498 | 92,754 | 83,618 | 75,903 | 74,206 | Upgrade
|
| EBIT Margin | 32.20% | 34.43% | 34.51% | 33.61% | 35.46% | Upgrade
|
| Effective Tax Rate | 20.26% | 22.03% | 19.06% | 29.80% | 25.10% | Upgrade
|
| Advertising Expenses | 28,662 | 31,186 | 27,861 | 25,260 | 27,110 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.